The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Treating patients with advanced-stage HL in the frontline and relapsed settings in 2024
Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, shares insights into the current management of patients with advanced-stage classical Hodgkin lymphoma (HL) in both the frontline and relapsed settings in the UK. In the frontline, clinicians are choosing between the ABVD and escalated BEACOPDac chemotherapy approaches, with the latter being more commonly used. Prof. Collins hopes that a more targeted approach will be available for patients in the future, with the addition of agents such as brentuximab vedotin or nivolumab to chemotherapy regimens. In the relapsed setting, treatment selection depends on the therapeutic approach deployed in the frontline. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda, Roche, Beigene, Astra Zeneca, Abbvie, Sobi, Kite / Gilead, BMS, Pfizer, SecuraBio.
